Sinovac Sells $500 Million Stake as Vaccine Nears Finish Line

Published December 7, 2020

One of China’s biggest generic drug makers is investing around $500 million to fund research and production of a frontrunner coronavirus vaccine candidate from Sinovac Biotech Ltd. that could be weeks away from being administered across the world.